Adiponectin is relevant to monitor glucose tolerance in human plasma and serum. So far, some novel biomarkers or clinical predictors for insulin resistance were claimed regulate glucose homeostasis. But, still need more data from clinical trial to establish as general biomarker in clinic.
it very easy , you have two majeur index to determin the resistance of insuline : homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI).
HOMA - IR = Insuline x Glucose / 22,5
Valeurs usuelles : entre 0,744 et 2,259
if you have HOMA>2,4 you have insulinoresistance
QUICKI = 1 / [log (insuline) + log (glucose)]
Valeurs moyenne : entre 0,338 et 0,403.
you can look this site : https://en.wikipedia.org/wiki/Homeostatic_model_assessment
Circulating levels of complement‑C1q TNF‑related proteins (CTRPs) have been recently observed to be linked with IR, but these proteins are not specific biomarkers for IR. They are also representative for Inflammation and Liver stiffness/damage.
Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance? (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118650)
Measuring insulin resistance is neither simple nor necessarily accurate. This is why several tests have been developed to quantify this metabolic phenomenon. Some of these tests are very reliable but complex, while others are less precise but more readily usable in clinical research due to simplicity and reduced invasiveness.
1-Hyperinsulinemic euglycemic glucose clamp is the gold standard for directly determining metabolic insulin sensitivity.
2-The homeostasis model assessment (HOMA)
3-The quantitative insulin sensitivity check index (QUICKI)
4-The oral glucose tolerance test (OGTT)
5-The minimal model analysis of the frequently sampled intravenous glucose tolerance test (FSIVGTT)